Female Health Company (FHCO)

[Latinachica]

FHCO, a lot of insider buying for the past month.
Check Fin Viz
One day toward in May, a few people loaded.
I would probably wait for a pull back.

EMA 4,8,13 1.21, 1.18, 1.16
BB .94 1.11 1.295
SMA 50, 200, 300 1.045, 1.069, 1.16.2
RSI 67.14
Either buy when it breaks 1.295 but that would be a day or swing trade
buy after a pull back, a great entry woul be a bounce of 1.11 and I would use 1.045 as a stop.
buy at 1.18 or 1.11 and keep it above 1.11
This should be kept on a daily watch

[wiltonio]

Opler Timothy has filed a new 13G, reporting 5.3% ownership in $FHCO - https://fintel.io/so/us/fhco

[growtheport]

I'm out. On to other opportunities.

[growtheport]

Welcome SA owners of FHCO.

A new tender offer from Brazil. Orders must now be prepaid (no surprise there). Where's the money they owe FHCO?

[growtheport]

Agreed. If it's called off, watch the stock pop. But the future is uncertain so it will probably be a temporary pop.

[Badfoot]

I started feeling that way after 2cd extention.Now its the 4th extention,Oct.31.For a companys share price to drop after each extention,it sure isn't looking like a merger will happen.

[antaltk]

FHCO is misleading it's investors. ISS still supports to vote AGAINST the MERGER. FHCO's latest press release is a TOTAL LIE.

VOTE AGAINST and REPORT the company to the SEC!

[Badfoot]

Revealed: Zika's life-threatening birth defects you DIDN'T know about http://www.dailymail.co.uk/health/article-3820535/Zika-s-life-threatening-birth-defects-DIDN-T-know-about.html

[growtheport]

Check out the coverage on SeekingAllpha. No one wants this dog of a deal.

[Badfoot]

Sept.20,2016 shareholders meeting on merger.

[Badfoot]

Go FHCO!!!

[Badfoot]

A/H LOOKING GOOD!!!

[Badfoot]

Possible merger soon.

[Badfoot]

A company in the green.

[growtheport]

So much for the rapid rise on PPS. And given they have botched the communication of this "merger" it's hard to get behind it.

Let's see what the call brings tomorrow.

[cowboyinvestor69]

LOL name change to FIASCO

[willlbone]

Name change to FISACO.

[willlbone]

Merger poison.

[ClarkKant]

Shorted to all hell today it looks like.

[growtheport]

Up 80% YTD.

It clearly was a low risk buy in the low $1 range. If they can diversify (both sales and products) we might have something here.

My only buy in my Roth looks great at a $1.41. My 401K needs this to be a bit above $3.

[JC8484]

The below link talks about the expansion in 2012.

femalehealth.com/press-release/?releaseid=2048278

The below link discusses the dividend cut.

http://femalehealth.com/press-release/?releaseid=2048082

I thought I remembered them talking about the expansion as one of reasons to cut dividends. However, based on timing of those press releases the expansion was paid for via normal cash flow.

I think one of the key reasons was the stock buyback plan, which the below link discusses.

http://femalehealth.com/press-release/?releaseid=2048111

Press releases from 2012 to current are here

http://femalehealth.com/investors/press-releases/

[growtheport]

You've got a few things mixed up. In July of 2014 they suspended the dividend when the stock was a bit above $5 share. The reason for this, according to the PR, was to fund additional marketing of FC2 and explore other products/business opportunities. They also hired a new CEO to lead this effort.

To date, no new products, a new strategy to market FC2 direct, and the CEO was out. The stock got crushed all the way down to $1.20 or so and has risen to it's current level.

I own 10K shares in two different accounts and still a bit under water. I did add in the low $1 range to average other buys.

No, I don't think they will bring back the dividend. They are trying to make this a growth company and diversify. Let's see if they can.

[JC8484]

Agree

[GhostInTheMatrix]

looks good here!!! real good!!

[JC8484]

Hello all
I've owned FHCO since 2012 and as far as I can tell the story has never really changed. I initially purchased when it was a little over $5 primarily for the dividend payment. I then added not that long ago when it was below $2. I now own 2,135 shares with a breakeven price of $2.34

When it was around $10/share in 2013 they made the announcement they were cutting dividends to utilize cash flow to expand production facility. You never really heard a lot about that expansion. But production has increased.

Once dividend was cut the share price plummeted fairly quick losing 1/2 its value, then it slowly sunk down to below $2.

I know many investors like stabilized earnings with a nice steady increase. However that is not what you get with this company. You are going to get increasing earnings, but the timing will be volatile with their sales model.

I listened to the last earnings call and they did emphasize how the female condom will be an extremely effective tool to stop pregnancies while the zika outbreak is going on, so hopefully we will see a nice increase in earnings.

Has anyone heard anything about the dividend being reinstated? I think that would help share price I think.

Good luck everyone, lets hope this picks up steam and pushes towards that $10 share price again.

[growtheport]

The worst should be over for FHCO.

Owned this one for a few years. Added to my position near the bottom given it was oversold.

I'd like to see this one over $2 in 2016. It should be with a smart acquisition and a direct to consumer sales strategy.

[GhostInTheMatrix]

Aug. 31, 2015 (GLOBE NEWSWIRE) -- The Female Health Company today announced that, its exclusive distributor in Brazil, Semina Indústria e Comércio Ltda has placed orders for 15 million FC2 Female Condoms.

http://femalehealth.com/press-release/?releaseid=2083185

[GhostInTheMatrix]

I remain optimistic about the Company’s future for the following reasons:

The unfortunate emergence of the Zika Virus epidemic in Brazil and other countries has created serious issues for infected women who may become pregnant. Women who are infected may give birth to children with brain deformities. As a result women in Brazil and other countries have been advised not to become pregnant. The female condom is an excellent product to prevent pregnancy during this epidemic.

http://finance.yahoo.com/news/female-health-company-reports-fiscal-133000390.html

[GhostInTheMatrix]

The Female Health Company Reports Fiscal 2016 First Quarter Operating Results

Highlights:

Unit sales increased 27% to 15.4 million from 12.2 million in the prior-year period.

Net revenues increased 24% to $8.2 million from $6.7 million in the prior-year period.

Gross profit up 41% to $5.4 million or 66% of net revenues, from $3.8 million, or 57% of net revenues, in the prior-year period.

Operating income improves 65% to $2.4 million for a 29% operating margin.

Diluted EPS up 67% to $0.05 per share from $0.03 per share in prior-year period.

$10 million Line of Credit signed with BMO Harris Bank.

[GhostInTheMatrix]

***FHCO JUST ADDED TO THE IHUB ZIKA BOARD***

http://investorshub.advfn.com/***Zika-virus-%28Shorts-and-Longs%29-%28ZIKA%29***-30666/

[pj McMulligan]

Just picked up 600 shares here, chart looking good for a pinch imo! :)

[JC8484]

Hello, I bought in January 2012 and have added to my position over time. Not a large position only 750 shares.

Do you see why the price is being pushed down so hard?

I would think that investors understood that temporarily stopping the dividend to fund their expansion to meet demand would be a positive. I.e. they don't need to go into debt to expand production.

Also, the company does not have a smooth income with extremely large orders coming at various intervals.

Just wondering what others thought, not very active chat here but maybe someone reads.

Later

[Penny Roger$]

$FHCO huge radar!!!

[motionjoe]

thanks, grow. appreciate it. will comtinue to monitor.

glta.

[growtheport]

Hi Joe. I'm new to this board, but not new to FHCO. In fact, I wrote an article on the company a few years back.

If you check the PPS, it did run for awhile. Female condom revenues are lumpy (in the countries where there are large orders) and recently they stopped paying a dividend. The stock fell from mid $5 all the way to low $3.

After the sell-off, I started buying again after cashing out around $6 (luckily before the fall). I'm now overweight the stock in my 401K and Roth IRA.

I'm thinking this one runs close to $5 by EOY given the recent positive news and excellent fundamentals. If their new sales strategy begins to show positive results (looking to boost US sales) 2015 could be a very good year for FHCO.

[motionjoe]

new to this board. cash flow positive, patents, stock repurchases, global distribution, n a market that is potentially 1/2 if the world. why hasn't it ran? demand, competition?

all of this is imo only

[Stockmater]

Natural retraction back here to start the day. Support above 4.18 seems to be legit. Expect early day shorts to get bored. The news on FHCO is mostly positive and I expect increased earnings in the December report. I'm long FHCO starting from 3.99 yesterday and have continued to add shares this AM.

[PAC]

FHCO 4.4 hearing continuation to 5.75 likely

[TheFinalCD]

20M FLOAT 50M CONDOMS==========LETS GO!!!

FHCO

http://finviz.com/quote.ashx?t=fhco&ty=c&ta=1&p=d

[shanak10]

http://ih.advfn.com/p.php?pid=nmona&article=63633605

[stocky101]

Expecting a nice bounce here to $5, just a bit oversold

[free_bee]

http://online.wsj.com/article/PR-CO-20131203-905533.html?dsk=y

FY2013 Highlights:

-- Company generates $11.8 million in cash from operations

-- Unit sales of 54.8 million units, 11% less than FY2012

-- Net revenues of $31.5 million

-- Operating income of $9.8 million

-- Diluted EPS of $0.50 vs. $0.53 in FY2012

-- Company increases quarterly cash dividend by 17% to $0.07 per share in March 2013

-- Company initiates review of option to potentially double production capacity

-- Operating margin of 31%

CHICAGO, Dec. 3, 2013 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), which manufactures and markets the FC2 Female Condom, today reported its financial results for the fourth quarter and fiscal year ended September 30, 2013. The Company will host an investor conference call today at 11:00 a.m. Eastern Time to discuss these operating results (see details below).

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

Management Comments

"The Company sold 54.8 million FC2 Female Condoms in Fiscal 2013, or 11% less than the record 61.6 million units sold in Fiscal 2012 but 36% above the previous record year in Fiscal 2009," stated O.B. Parrish, the Company's Chairman and Chief Executive Officer. "We believe the decrease in unit sales was due to public sector purchasing patterns and does not reflect any decrease in underlying demand for the product. The Company periodically experiences quarterly and/or annual variations in unit sales unrelated to underlying demand. On a longer-term basis, we believe that demand for FC2 remains robust and continues to grow at impressive rates, as reflected by the following: a 19% average annual compound unit growth rate during the eight-year period from Fiscal 2005 through Fiscal 2013; expansion in distribution to 143 countries in Fiscal 2013, compared with 138 countries in the previous fiscal year; and an increase of 43% in the number of locations where FC2 is available in New York City, from 1,001 in Fiscal 2012 to 1,436 in Fiscal 2013."

"The Company's overall financial performance was solid in Fiscal 2013. Despite an 11% decrease in unit sales, the Company's operating profit margin remained healthy at 31% of net revenues. During the fiscal year ended September 30, 2013 we generated $11.8 million in positive cash flow from operations, cash on hand increased 68% to $8.9 million after the payment of $7.5 million in dividends, and shareholders' equity increased 30% to $31.4 million. In early Fiscal 2013, the Company completed a 20% expansion in its production capacity to 100 million units annually. In view of pending tenders and other positive market indicators, we are currently exploring an option that would permit us to further double our production capacity on a modular basis as needed," concluded Parrish.

"We believe that several factors will continue to drive increased demand for FC2, including the feminization of HIV/AIDS and its expanding role in family planning," continued Parrish. "The global HIV/AIDS pandemic is currently the leading cause of death among women of reproductive age (15-44), and the female condom is the only female-controlled product that provides dual protection against both HIV/AIDS and unintended pregnancy. The Bill and Melinda Gates Foundation and the Government of the United Kingdom have initiated the Family Planning 2020 program (FP2020), which is designed to increase access to contraceptives to an additional 120 million women in 69 developing countries by the year 2020. In addition, global funding to battle sexually-transmitted diseases and to expand utilization of contraceptives has increased, as evidenced by $4.6 billion in commitments to fund the FP2020 program and the U.K. Government's commitment to provide $1.5 billion in funding to battle HIV/AIDS, Tuberculosis and Malaria over a three-year period."

Fiscal Year Results

For the fiscal year ended September 30, 2013, unit sales decreased 11% to 54.8 million units compared with 61.6 million units in FY2012. Net revenues decreased 10% to approximately $31.5 million in FY2013, compared with approximately $35.0 million in FY2012.

In the fiscal year ended September 30, 2013, gross profit decreased 15% to $17.5 million, or 56% of net revenues, compared with $20.6 million, or 59% of net revenues, in the fiscal year ended September 30, 2012.

Operating expenses decreased 20% in FY2013 to $7.7 million, compared with operating expenses of $9.7 million in the fiscal year ended September 30, 2012. The decrease was primarily due to a reduction in incentive awards, partially offset by increased spending in education and training and consulting expenses.

Operating income decreased 11% to $9.8 million in the fiscal year ended September 30, 2013, compared with $10.9 million in FY2012. The decrease is primarily due to the decrease in unit sales.

The Company reported net income of $14.3 million, or $0.50 per diluted share, in the fiscal year ended September 30, 2013, for a decrease of 6% when compared with net income of $15.3 million, or $0.53 per diluted share, in the fiscal year ended September 30, 2012. Currency losses of $101,288 and $148,269 were recorded in the fiscal years ended September 30, 2013 and 2012, respectively. The Company recorded a net tax benefit for FY2013 of $4.4 million, versus $4.5 million in FY2012. As of September 30, 2013, tax loss carryforwards of $19.2 million federal, $17.2 million state and $63.2 million in the U.K. were available to offset future earnings.

Fourth Quarter Results

For the three months ended September 30, 2013, unit sales decreased 52% when compared with the fourth quarter of FY2012. Net revenues decreased 52% to $4.8 million, compared with $9.9 million in the three months ended September 30, 2012.

Gross profit decreased 60% to $2.3 million, or 48% of net revenues, in the most recent quarter, compared with $5.8 million, or 58% of net revenues, in the fourth quarter of FY2012.

Operating expenses for the quarter ended September 30, 2013 decreased 79% to $0.5 million, versus operating expenses of $2.6 million in the fourth quarter of FY2012. The decrease was primarily due to a reduction in incentive awards.

Operating income decreased 45% to $1.7 million in the three months ended September 30, 2013, compared with $3.2 million in the prior-year quarter. The decrease was primarily due to lower unit sales.

The Company reported net income of $6.6 million, or $0.23 per diluted share, which represented a 19% decrease when compared with net income of $8.2 million, or $0.29 per diluted share, in the fourth quarter of FY2012. The Company recorded a currency loss of $1,115 and $78,975 during the quarters ended September 30, 2013 and 2012, respectively. The Company recorded a net tax benefit of $4.9 million in the fourth quarter versus a net tax benefit of $5.1 million in the prior-year quarter.

Cash Dividends

During FY2013, the Company generated positive cash flow from operations of approximately $11.8 million, paid two quarterly cash dividends of $0.06 per share each and two quarterly cash dividends of $0.07 per share each, and maintained a debt-free balance sheet. The amount of cash on the Company's balance sheet increased 68% during FY2013, to $8.9 million as of September 30, 2013, versus $5.3 million as of September 30, 2012. In March 2013, the Company's announced the 2(nd) increase in its quarterly dividend since it started paying cash dividends in FY2010. On November 6, 2013, the 16(th) consecutive quarterly cash dividend was paid in the amount of $0.07 per share. The Company's current quarterly cash dividend of $0.07 per share provides shareholders with an annualized yield of 3.0% based upon the closing price of FHCO shares on December 2, 2013.

Investor Conference Call

As previously announced, The Female Health Company will host an investor conference call at 11:00 a.m. Eastern Time, today, December 3, 2013, to discuss its fourth quarter operating results and other topics of interest. Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call", a few minutes before 11:00 a.m. EST.

A replay of the conference call will be available one hour after the call through 9:00 a.m. EST on Tuesday, December 10, 2013 by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the conference ID 10037276. After Tuesday, December 10, 2013, the replay of the call will be available on the Company's website at www.femalehealth.com.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom(R) (FC2), which is available in the U.S. and approximately 143 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom(R), including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom(R) is the only currently available female-controlled product approved by the FDA that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding underlying demand for FC2 and the results of pending tenders, possible options to expand manufacturing capacity and the continuation of cash dividends in future periods. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2013. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [e-mail]

(Financial Highlights Follow)


The Female Health Company
Unaudited Condensed Consolidated Balance Sheets

September 30,
------------------------
2013 2012
----------- -----------
Cash $ 8,922,430 $ 5,295,462
Accounts receivable, net 2,362,165 7,268,917
Income tax receivable 78,440 27,369
Inventory, net 2,459,417 1,458,199
Prepaid expenses and other current assets 514,213 624,268
Deferred income taxes 2,552,000 2,152,000
---------- ----------
Total current assets 16,888,665 16,826,215

Other non-current assets 138,458 122,336
Plant and equipment, net 2,094,830 2,349,876
Deferred income taxes 16,048,000 11,148,000
---------- ----------
Total assets $35,169,953 $30,446,427
========== ==========

Accounts payable $ 904,049 $ 1,775,327
Accrued expenses and other current liabilities 1,540,457 1,120,302
Accrued compensation 962,693 2,964,812
---------- ----------
Total current liabilities 3,407,199 5,860,441

Deferred rent 66,799 90,902
Deferred grant income 57,819 82,650
Deferred income taxes 235,179 194,244
---------- ----------
Total liabilities 3,766,996 6,228,237

Total stockholders' equity 31,402,957 24,218,190
---------- ----------
Total liabilities and stockholders' equity $35,169,953 $30,446,427
========== ==========


The Female Health Company
Unaudited Condensed Consolidated Income Statements

Three Months Ended
September 30,
--------------------------
2013 2012
------------ ------------

Net revenues $ 4,789,187 $ 9,911,701

Cost of sales 2,514,224 4,161,537
----------- -----------

Gross profit 2,274,963 5,750,164

Operating expenses 532,983 2,564,791
----------- -----------

Operating income 1,741,980 3,185,373

Interest and other expense (30,421) (551)
Foreign currency transaction loss (1,115) (78,975)
----------- -----------

Income before income taxes 1,710,444 3,105,847

Income tax benefit (4,879,728) (5,079,358)
----------- -----------
Net income $ 6,590,172 $ 8,185,205
=========== ===========

Net income per basic common share outstanding $ 0.23 $ 0.29

Basic weighted average common shares
outstanding 28,400,776 28,180,001

Net income per diluted common share
outstanding $ 0.23 $ 0.29

Diluted weighted average common shares
outstanding 28,759,584 28,678,081

Cash dividends declared per common share $ 0.07 $ 0.06


The Female Health Company
Unaudited Condensed Consolidated Income Statements

Year Ended
September 30,
--------------------------
2013 2012
------------ ------------

Net revenues $ 31,456,778 $ 35,033,897

Cost of sales 13,952,420 14,412,884
----------- -----------

Gross profit 17,504,358 20,621,013

Operating expenses 7,714,761 9,681,083
----------- -----------

Operating income 9,789,597 10,939,930

Interest and other income 245,545 362
Foreign currency transaction loss (101,288) (148,269)
----------- -----------

Income before income taxes 9,933,854 10,792,023

Income tax benefit (4,408,744) (4,507,298)
----------- -----------
Net income $ 14,342,598 $ 15,299,321
=========== ===========

Net income per basic common share outstanding $ 0.51 $ 0.55

Basic weighted average common shares
outstanding 28,376,607 27,693,721

Net income per diluted common share
outstanding $ 0.50 $ 0.53

Diluted weighted average common shares
outstanding 28,726,478 28,933,144

Cash dividends declared per common share $ 0.26 $ 0.22

SOURCE The Female Health Company

/CONTACT: William R. Gargiulo, Jr., 231.526.1244, or Michele Greco, CFO, 312.595.9123

/Web site: http://www.femalehealth.com

[mlkrborn]

FHCO $7.14

1:30AM Female Health extends stock repurchase program until Dec 31, 2013 (FHCO) 7.14 : Co announces the extension of its stock repurchase program through December 31, 2013. The program was previously due to expire at the end of calendar year 2012 and has a repurchase cap of 3 mln shares of common stock. The co has repurchased ~2 mln shares under the program, and ~1 mln shares remain for potential repurchase.

[Penny Roger$]

~ $FHCO ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $FHCO ~ Earnings expected on Friday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=FHCO&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=FHCO&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/FHCO?
~ OTC Markets: http://www.otcmarkets.com/stock/FHCO/company-info
~ Google Finance: http://www.google.com/finance?q=FHCO
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=FHCO#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=FHCO+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=FHCO
Finviz: http://finviz.com/quote.ashx?t=FHCO
~ BusyStock: http://busystock.com/i.php?s=FHCO&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=FHCO&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=FHCO
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=FHCO
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=FHCO
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=FHCO
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=FHCO
~ MarketWatch: http://www.marketwatch.com/investing/stock/FHCO/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=FHCO
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[Penny Roger$]

Gotta love this board..

[Penny Roger$]

~ $FHCO ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $FHCO ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=FHCO&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=FHCO&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/FHCO?
~ OTC Markets: http://www.otcmarkets.com/stock/FHCO/company-info
~ Google Finance: http://www.google.com/finance?q=FHCO
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=FHCO#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=FHCO+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=FHCO
Finviz: http://finviz.com/quote.ashx?t=FHCO
~ BusyStock: http://busystock.com/i.php?s=FHCO&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=FHCO&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=FHCO
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=FHCO
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=FHCO
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=FHCO
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=FHCO
~ MarketWatch: http://www.marketwatch.com/investing/stock/FHCO/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=FHCO
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=FHCO&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[ambulance_blues]

I think it might explain some of the selling last week. That's why I say the article may have presented a buying oportunity, as I don't think one state (Uganda) is representative of the company's global prospects.

[trendseeker]

AB, I'm wondering whether this article partially explains the recent selloff. I'm hoping it was just a typical small cap pullback but this article makse me wonder there's some fundamental concern about product acceptance.

Institutional buying still looks good, so I'm hanging onto my postion for now although I'm antsy about the ability of this market to maintain itself into the latter part of 2009.

[ambulance_blues]

Article in TIME magazine.

A recent article in TIME may have created a buying opportunity.

http://www.time.com/time/world/article/0,8599,1919311,00.html

The article talks about some resistance to female condom acceptance in Uganda. However, this could be more a reflection of the more expensive and inferior FC1 model. The rollout of FC2 is expected to increase, not decrease, market penetration worldwide. In addition, from the 10Q, Uganda does not currently appear to be a significant client. The largest incude Zimbabwe, South Africa, and US -- all of which are experiencing growth. However, Uganda's skepticism of the female condom is not totally benign, as it could be a larger sign of attitudinal shift regarding AIDS prevention strategies in other 3rd world countries. So far we have no evidence of this. But it bears watching.

[ambulance_blues]

Replay of Q3 conference call available online.

http://www.femalehealthcompany.com/conferencecalls.html